ATA Inc

ATAI Life Sciences N.V. a clinical-stage biopharmaceutical company engages in acquiring incubating and developing various therapeutics to treat depression anxiety addiction and other mental health disorders. Its principal clinical programs include RL-007 a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917 a deuterated etifoxine for anxiety disorders; VLS-01 a NN-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002 an oral formulation of ibogaine a cholinergic glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01 an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101 a subcutaneous formulation of R-ketamine as a therapy for psychiatric indications initially focused on TRD; and KUR-101 a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin Germany with offices in New York and London.